Keyphrases
Cost-effectiveness
100%
Second-line Treatment
100%
Sorafenib
100%
Advanced Renal Cell Carcinoma
100%
Best Supportive Care
83%
Quality-adjusted Life Years
66%
Clinical Efficacy
33%
Healthcare Settings
16%
On-state Current
16%
Germany
16%
Phase II Trial
16%
Sensitivity Analysis
16%
UK Practice
16%
EQ-5D
16%
Tariffs
16%
Health Benefits
16%
UK National Health Service
16%
Life-years Gained
16%
Decision-analytic Model
16%
Incremental Cost
16%
Parameter Influence
16%
Drug Costs
16%
Randomized Phase III Trial
16%
Bayes
16%
Effectiveness Parameter
16%
Parameter Uncertainty
16%
Willingness-to-pay Threshold
16%
Utility Costs
16%
Utility Value
16%
Cost Data
16%
Cost-effective Use of Resources
16%
Probabilistic Sensitivity Analysis
16%
One-way Sensitivity Analysis
16%
Health State Utility
16%
Sunitinib
16%
Sorafenib Treatment
16%
Nexavar
16%
Mean Gain
16%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Renal Cell Carcinoma
100%
Sorafenib
100%
Quality Adjusted Life Year
62%
Clinical Effectiveness
25%
Socialized Medicine
12%
Health Status
12%
Drug Cost
12%
Sunitinib
12%
Health Care
12%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Sorafenib
100%
Phase II Trials
12%
Health Status
12%
Sunitinib
12%
Phase III Trials
12%